Physician profile
Yoongie E Min
NPI 1063572865
$4,937.56
in general payments reported to CMS, 2019-2025
12 companies · $457 in 2025
The $457 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $837 · 2021: $448 · 2022: $562 · 2023: $432 · 2024: $414 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.71 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,407.30 | 2019-2025 | Acuvue |
| Johnson & Johnson Surgical Vision, INC. | $1,099.85 | 2019 | |
| Alcon Vision LLC | $537.13 | 2019-2025 | Dailies Total1, Total30, Clareon |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $468.53 | 2019-2021 | |
| Abb Con-Cise Optical Group LLC | $325.72 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $238.45 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $234.79 | 2022-2025 | Infuse, Biotrue One Day, Miebo |
| Coopervision INC. | $189.79 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Oyster Point Pharma, INC. | $153.66 | 2022 | |
| Kala Pharmaceuticals, INC. | $144.97 | 2021 | |
| Lombart Brothers, INC. | $113.26 | 2019 | |
| Harrow Eye, LLC | $24.11 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoongie Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.